Trials / Completed
CompletedNCT02928406
A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
An Open Label, Single Arm, Multicenter, Safety Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,004 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This Phase IIIb, multicenter study will assess the safety of atezolizumab as second- to fourth-line treatment for participants with locally advanced or metastatic urothelial or non-urothelial cancer of the urinary tract in addition to evaluate the efficacy of atezolizumab and potential tumor biomarkers associated with atezolizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atezolizumab | Atezolizumab 1200 milligrams (mg) will be administered by intravenous (IV) infusion Q3W. |
Timeline
- Start date
- 2016-11-30
- Primary completion
- 2022-12-12
- Completion
- 2022-12-12
- First posted
- 2016-10-10
- Last updated
- 2024-04-04
- Results posted
- 2024-04-04
Locations
175 sites across 32 countries: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Czechia, Denmark, Estonia, Germany, Greece, Hungary, India, Ireland, Italy, Lebanon, Lithuania, Netherlands, Poland, Portugal, Romania, Russia, Saudi Arabia, Slovakia, Spain, Switzerland, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT02928406. Inclusion in this directory is not an endorsement.